#KPTI

Lead report

Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook

Karyopharm (KPTI) Q2 results: GAAP EPS -$2.32 miss, revenue $33.43M beats (-11.9% Y/Y), cash $65.4M.